Paper Information

Title: 

IN SILICO COMPARISON OF P-GLYCOPROTEIN INHIBITOR COMPOUNDS

Type: POSTER
Author(s): SHAYANFAR ALI*,TAMIZI E.
 
 *FACULTY OF PHARMACY AND STUDENT RESEARCH COMMITTEE, TABRIZ UNIVERSITY OF MEDICAL SCIENCES
 
Name of Seminar: IRANIAN CONGRESS OF PHYSIOLOGY AND PHARMACOLOGY
Type of Seminar:  CONGRESS
Sponsor:  PHYSIOLOGY AND PHARMACOLOGY SOCIETY, MASHHAD UNIVERSITY OF MEDICAL SCIENCE
Date:  2009Volume 19
 
 
Abstract: 

Overexpression of P-glycoprotein is one of the important reasons for pharmacoresistant in cancer and epilepsy. Using of drugs with P-glycoprotein inhibitory effects can enhancement bioavailability and efficacy of drugs.
In literature, some P-glycoprotein inhibitor reported and efficacy of these drugs approved each one with different methods such as cell-culture, animal lab and so on. There isn't any comparison of P-glycoprotein compounds to deliver suitable drug for using these compounds in clinic and as a lead compound to design other pharmaceutical compound thus using of in-silico models such as pharmaalgorithm that is powerful software to predict physicochemical and pharmacokinetic of drugs can help to comparison of P-glycoprotein inhibitor compounds.
Over than sixty pharmaceutical and natural compounds with P-glycoprotein inhibitory effects were gathered from literatures. The potency of these effects for P-glycoprotein inhibition is calculated with pharma-algorithm software. This study show the some compound such as Zosuquidar trihydrochloride, Tariquider, Aureobasidin A, S9788 and so on are the potent P-glycoprotein inhibitors thus these compounds can be used in clinic to enhance bioavailability and efficacy of drugs relevant with P-glycoprotein also the pharmaceutical chemist can be used these structures as lead compounds to design other pharmaceutical compounds to inhibit P-glycoprotein.

 
Keyword(s): P-GLYCOPROTEIN INHIBITOR, ANTICANCER AND ANTIEPILEPTIC DRUGS, PHARMAALGORITHM SOFTWARE
 
Yearly Visit 20   tarjomyar
 
Latest on Blog
Enter SID Blog